Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic

Bibliography

• Nature lipidomics gateway. Available from: http://www.lipidmaps.org/2009
   Google Scholar
• Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9:162-76
   PubMed Web of Science ®Google Scholar
• Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009;23:49-59
   PubMed Web of Science ®Google Scholar
• Boyanovsky BB, Webb NR. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther 2009;23:61-72
   PubMed Web of Science ®Google Scholar
• Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31
   PubMed Web of Science ®Google Scholar
• Karabina SA, Brocheriou I, Le Naour G, et al. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J 2006;20:2547-9
   PubMed Web of Science ®Google Scholar
• Chen CH. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol 2004;15:337-41
   PubMed Web of Science ®Google Scholar
• Turunen P, Puhakka H, Rutanen J, et al. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis 2005;179:27-33
   PubMed Web of Science ®Google Scholar
• Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9
   PubMed Web of Science ®Google Scholar
• Mohler ER III, Sarov-Blat L, Shi Y, et al. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol 2008;28:850-5
   PubMed Web of Science ®Google Scholar
• Packard CJ, O'reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease. N Engl J Med 2000;343:1148-55
   PubMed Web of Science ®Google Scholar
• Ballantyne C, Cushman M, Psaty B, et al. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3-11
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2:529-35
   PubMedGoogle Scholar
• Suckling KE. The ideal model in atherosclerosis and dyslipidaemia - does it exist? Expert Opin Drug Discov 2007;1:507-11
   Web of Science ®Google Scholar
• Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group V secretory phospholipase A2 promotes atherosclerosis. Evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007;27(3):600-6
   PubMed Web of Science ®Google Scholar
• Boyanovsky B, Zack M, Forrest K, Webb NR. The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol 2009;29:532-8
   PubMed Web of Science ®Google Scholar
• Sato H, Kato R, Isogai Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008;283:33483-97
   PubMed Web of Science ®Google Scholar
• Kimura-Matsumoto M, Ishikawa Y, Komiyama K, et al. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 2008;196:81-91
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-norfolk prospective population study. Arterioscler Thromb Vasc Biol 2005;25:839-46
   PubMed Web of Science ®Google Scholar
• Parks BW, Lusis AJ, Kabarowski JHS. Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006;26(12):2703-9
   PubMed Web of Science ®Google Scholar
• Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005;32:417-23
   PubMed Web of Science ®Google Scholar
• GSK press release: Available from: http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10144.htm.2009
   Google Scholar
• The stabilization of atherosclerotic plaque by initiation of darapladib therapy trial (STABILITY). ClinicalTrials.gov 2009
   Google Scholar
• FRANCIS-ACS Trial: A study of the safety and efficacy of A 002 in subjects with acute coronary syndromes. 2009
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Suckling K. What is the future for drug development in atherosclerosis and dyslipidaemia? Expert Opin Drug Discov 2009;4:1-3
   PubMed Web of Science ®Google Scholar
• Oslund RC, Cermak N, Gelb MH. Highly specific and broadly potent inhibitors of mamB malian secreted phospholipases A2. J Med Chem 2008;51:4708-14
   PubMed Web of Science ®Google Scholar
• Pinto IL, Oyd HF, Hickey DMB. Natural product derived inhibitors of lipoprotein associated phospholipase A(2), synthesis and activity of analogues of SB-253514. Bioorganic Med Chem Lett 2000;10:2015-17
   PubMed Web of Science ®Google Scholar
• Suckling KE. Top down meets bottom-up. The critical interface for drug discovery. International atherosclerosis society commentary. Available from: http://www.athero.org/commentaries/comm650.asp. IAS commentary 2009
   Google Scholar
• Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009. In press (PMID 19129734)
   PubMedGoogle Scholar
• Leite J, Vaishnav U, Puglisi M, et al. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc Disord 2009;9:7
   PubMed Web of Science ®Google Scholar
• Shaposhnik Z, Wang X, Trias J, et al. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2009;50:623-9
   PubMed Web of Science ®Google Scholar
• Benson GM, Grimsditch DC, Milliner KJ, et al. Anti-atherosclerotic effect of SB-244323, a lipoprotein-associated phospholipase A2 inhibitor in WHHL rabbits [abstract]. Atherosclerosis 2000;151:66
   Google Scholar
• Wilensky RL, Shi Y, Mohler ER III, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;4:1059-66
   Google Scholar
• Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009;73:649-58
   Google Scholar
• Duivenvoorden R, Nederveen AJ, de GE, Kastelein JJ. Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 2007;18:613-21
   PubMed Web of Science ®Google Scholar
• Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008;7:517-29
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB, et al.; the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006;354:1253-63
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82
   PubMed Web of Science ®Google Scholar
• Mohler ER III, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51:1632-41
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009;23:93-101
   PubMed Web of Science ®Google Scholar